ATE237332T1 - Efavirenz enthaltende gepresste tablettenformulierug - Google Patents
Efavirenz enthaltende gepresste tablettenformulierugInfo
- Publication number
- ATE237332T1 ATE237332T1 AT99925793T AT99925793T ATE237332T1 AT E237332 T1 ATE237332 T1 AT E237332T1 AT 99925793 T AT99925793 T AT 99925793T AT 99925793 T AT99925793 T AT 99925793T AT E237332 T1 ATE237332 T1 AT E237332T1
- Authority
- AT
- Austria
- Prior art keywords
- tablet formulation
- formulation containing
- efavirenz
- pressed tablet
- containing efavirenz
- Prior art date
Links
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 title abstract 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 title abstract 3
- 229960003804 efavirenz Drugs 0.000 title abstract 3
- 239000007916 tablet composition Substances 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 239000007891 compressed tablet Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8692198P | 1998-05-27 | 1998-05-27 | |
| GBGB9815800.9A GB9815800D0 (en) | 1998-07-21 | 1998-07-21 | Compressed tablet formulation |
| PCT/US1999/011464 WO1999061026A1 (en) | 1998-05-27 | 1999-05-24 | Efavirenz compressed tablet formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE237332T1 true ATE237332T1 (de) | 2003-05-15 |
Family
ID=26314071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99925793T ATE237332T1 (de) | 1998-05-27 | 1999-05-24 | Efavirenz enthaltende gepresste tablettenformulierug |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1083901B1 (de) |
| JP (1) | JP4000354B2 (de) |
| AT (1) | ATE237332T1 (de) |
| AU (1) | AU761182B2 (de) |
| CA (1) | CA2332876C (de) |
| CO (1) | CO5070643A1 (de) |
| CY (1) | CY1113191T1 (de) |
| DE (1) | DE69906963D1 (de) |
| DK (1) | DK1332757T3 (de) |
| ES (1) | ES2388849T3 (de) |
| PE (1) | PE20000559A1 (de) |
| PT (1) | PT1332757E (de) |
| SI (1) | SI1332757T1 (de) |
| WO (1) | WO1999061026A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72207C2 (uk) | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| US20030124186A1 (en) * | 2001-11-27 | 2003-07-03 | Hussain Munir A. | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| EP1545206B1 (de) | 2002-07-24 | 2020-03-04 | Children's Hospital Medical Center | Zusammensetzungen und produkte, die enantiomeres equol enthalten, sowie verfahren zu ihrer herstellung |
| MXPA05007016A (es) | 2003-01-14 | 2005-09-12 | Gilead Sciences Inc | Composiciones y metodos para terapia antiviral de combinacion. |
| US7198653B2 (en) * | 2003-07-31 | 2007-04-03 | Delavau Llc | Calcium carbonate granulation |
| JP2005089396A (ja) * | 2003-09-19 | 2005-04-07 | Pola Chem Ind Inc | イソフラボン含有経口投与組成物 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| US9198862B2 (en) | 2005-07-22 | 2015-12-01 | Rubicon Research Private Limited | Dispersible tablet composition |
| WO2007013047A2 (en) * | 2005-07-29 | 2007-02-01 | Ranbaxy Laboratories Limited | Water-dispersible anti-retroviral pharmaceutical compositions |
| UA95093C2 (uk) * | 2005-12-07 | 2011-07-11 | Нікомед Фарма Ас | Спосіб одержання кальцієвмісної сполуки |
| US20090088424A1 (en) * | 2007-08-17 | 2009-04-02 | Ilan Zalit | Methods and compositions for controlling the bioavailability of poorly soluble drugs |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| WO2011131943A2 (en) | 2010-04-20 | 2011-10-27 | Cipla Limited | Pharmaceutical compositions |
| TWI599360B (zh) * | 2010-05-11 | 2017-09-21 | 健生藥品公司 | 醫藥調配物 |
| EP2447255A1 (de) | 2010-10-14 | 2012-05-02 | Lonza Ltd. | Verfahren zur Synthese von zyklischen Carbamaten |
| EP2441759A1 (de) | 2010-10-14 | 2012-04-18 | Lonza Ltd. | Verfahren zur Synthese von zyklischen Carbamaten |
| SG11201401583YA (en) * | 2011-10-17 | 2014-09-26 | Lexicon Pharmaceuticals Inc | Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate |
| CN103508973B (zh) * | 2012-06-25 | 2016-04-27 | 上海迪赛诺药业有限公司 | 制备依非韦伦i型结晶的方法 |
| IN2013MU03370A (de) | 2013-10-25 | 2015-09-25 | Cipla Ltd | |
| RU2759544C1 (ru) * | 2021-01-29 | 2021-11-15 | Общество с ограниченной ответственностью "АМЕДАРТ" | Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции |
| CN113499441A (zh) * | 2021-08-05 | 2021-10-15 | 上海合全医药有限公司 | 一种药用糖包衣液及其制备方法 |
| CN113999543B (zh) * | 2021-10-29 | 2022-11-04 | 广西华纳新材料股份有限公司 | 一种钙-硅核壳结构纳米碳酸钙的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1694295A (en) * | 1994-01-28 | 1995-08-15 | Merck & Co., Inc. | Benzoxazinones as inhibitors of hiv reverse transcriptase |
| US5633405A (en) * | 1995-05-25 | 1997-05-27 | Merck & Co., Inc. | Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one |
| BR9809127A (pt) * | 1997-05-17 | 2000-08-01 | Glaxo Group Ltd | Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente |
-
1999
- 1999-05-21 CO CO99031381A patent/CO5070643A1/es unknown
- 1999-05-21 PE PE1999000431A patent/PE20000559A1/es not_active IP Right Cessation
- 1999-05-24 WO PCT/US1999/011464 patent/WO1999061026A1/en not_active Ceased
- 1999-05-24 EP EP99925793A patent/EP1083901B1/de not_active Expired - Lifetime
- 1999-05-24 SI SI9931069T patent/SI1332757T1/sl unknown
- 1999-05-24 CA CA002332876A patent/CA2332876C/en not_active Expired - Lifetime
- 1999-05-24 ES ES03076054T patent/ES2388849T3/es not_active Expired - Lifetime
- 1999-05-24 AT AT99925793T patent/ATE237332T1/de not_active IP Right Cessation
- 1999-05-24 DE DE69906963T patent/DE69906963D1/de not_active Expired - Lifetime
- 1999-05-24 JP JP2000550486A patent/JP4000354B2/ja not_active Expired - Lifetime
- 1999-05-24 DK DK03076054.0T patent/DK1332757T3/da active
- 1999-05-24 AU AU42010/99A patent/AU761182B2/en not_active Expired
- 1999-05-24 PT PT03076054T patent/PT1332757E/pt unknown
-
2012
- 2012-08-29 CY CY20121100778T patent/CY1113191T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69906963D1 (de) | 2003-05-22 |
| EP1083901B1 (de) | 2003-04-16 |
| JP2002516281A (ja) | 2002-06-04 |
| AU761182B2 (en) | 2003-05-29 |
| CA2332876C (en) | 2008-07-08 |
| WO1999061026A1 (en) | 1999-12-02 |
| JP4000354B2 (ja) | 2007-10-31 |
| ES2388849T3 (es) | 2012-10-19 |
| CO5070643A1 (es) | 2001-08-28 |
| CY1113191T1 (el) | 2016-04-13 |
| DK1332757T3 (da) | 2012-09-24 |
| PE20000559A1 (es) | 2000-07-05 |
| PT1332757E (pt) | 2012-09-03 |
| SI1332757T1 (sl) | 2012-10-30 |
| AU4201099A (en) | 1999-12-13 |
| CA2332876A1 (en) | 1999-12-02 |
| EP1083901A1 (de) | 2001-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE237332T1 (de) | Efavirenz enthaltende gepresste tablettenformulierug | |
| EP1268412B8 (de) | Sulfonamido-substituierte verbrückte bicycloalkylderivative | |
| SE9500422D0 (sv) | New oral pharmaceutical dosage forms | |
| HUP0301868A2 (hu) | Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz | |
| DK0954314T3 (da) | Doseringsformer til bedring af mandlig erektionsdefekt | |
| HUP0203556A2 (hu) | Oxkarbazepint tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| MY136173A (en) | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor | |
| CY1107512T1 (el) | Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους | |
| TR200101261T2 (tr) | Uzun süreli salınımlı ranolazin formülasyonları. | |
| EP1210941A3 (de) | Pharmazeutische Zusammensetzungen enthaltend Ritonavir (ABT-538) in Kombination mit Indinavir (MK-639) und deren Verwendung zur Behandlung von AIDS | |
| WO2004030611A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| DK0680326T3 (da) | Farmaceutisk formulering af nikotinafhængighed. | |
| ATE291914T1 (de) | Zolmitriptanhaltige arzneizusammensetzungen | |
| HUP0004544A2 (hu) | Angiotenzin-átalakító enzim inhibitora és diuretikum kombinációjának alkalmazása mikrokeringési rendellenességek kezelésére szolgáló gyógyászati készítmény előállítására | |
| AP2003002716A0 (en) | Medicinal compositions containing propenone derivatives. | |
| ATE308328T1 (de) | Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen | |
| ATE301999T1 (de) | Racecadotril enthaltende trockene pulverformulierung | |
| NO960775L (no) | Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner | |
| IL132853A (en) | Composition for modulating the human sexual response | |
| HUP9901353A2 (hu) | ACE-inhibitorok alkalmazása diszpepsziás tünetek kezelésére alkalmas gyógyszerkészítmény előállítására | |
| BR0209155A (pt) | Tablete farmacêutico tendo um teor de api elevado | |
| MY121604A (en) | Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt | |
| SE0001916D0 (sv) | Novel formulation | |
| DE59910944D1 (de) | Transdermales therapeutisches system zur anwendung von candesartan | |
| HUP0004461A2 (hu) | Apoliprotein B kiválasztást/mikroszomális trigliceridtranszfer-proteint gátló anyag alkalmazása gyógyászati készítmények előállítására és a fenti gyógyászati készítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REZ | Deleted due to withdrawal | ||
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |